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We studied the expression of transcription factors RUNX2 and Osterix after addition of a 
concentrate of osteogenic-conditioned medium to the culture medium for osteogenic differen-
tiation of mesenchymal stem cells (MSC). The obtained concentrate of osteogenic-conditioned 
medium containing a complex of bioactive substances with a molecular weight >10 kDa pro-
vided MSC differentiation into osteoblasts, which was confirmed by high level of expression 
of transcription factors RUNX2 and Osterix in comparison with the negative control. The 
highest expression of transcription factor Osterix was revealed on day 14 of MSC culturing in 
the presence of osteogenic supplement StemPro (positive control) and the studied concentrate 
of osteogenic-conditioned medium.
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Mesenchymal stem cells (MSC) hold great promise 
for cell therapy, tissue engineering, and regenerative 
medicine. One of the modern tasks of regenerative 
medicine is creation of bone grafts based on popula-
tions of living cells and paracrine factors [15]. Tis-
sue engineering in situ, a new strategy for repairing 
bone defects [6], requires both biomimetic cell carriers 
and osteoinductors for in situ technologies. Isolation 
and use of paracrine factors are general approaches 
in enhancing the regeneration process based on MSC 
therapy [11]. The most widely used paracrine factors 
exhibiting osteoinductive properties are bone mor-
phogenetic protein-1 (BMP), fibroblast growth factor 
(bFGF), insulin-like growth factor-1 (IGF-1), stromal 
cell factor 1 (SDF-1), etc. [14,16].
In parallel, the possibility of using osteogenic-
conditioned media for induction of osteoblastic dif-
ferentiation of MSC is studied. It was shown that 
osteogenic-conditioned medium from human perioste-
um-derived cells (hPDC) stimulated the expression of 
receptor activator of NF-κB ligand (RANKL) and pro-
moted osteoclastogenesis [9]. Interesting results were 
demonstrated by a group of researchers demonstrating 
a decrease in the level of some cytokines, chemokines, 
and growth factors not exhibiting direct osteoinduc-
tive activity in the conditioned medium obtained after 
culturing of adipose tissue-derived stem cells (ASC) 
and stem cells from human exfoliated deciduous teeth 
(SHED) with osteoinductive supplement [8]. We be-
lieve that a concentrate osteogenic-conditioned me-
dium obtained from MSC after exposure to generally 
accepted combination of substances with osteoinduc-
tive activity can be used as osteoinductive supplement 
[13]. To verify this hypothesis, it was necessary to 
study the expression of transcription factors RUNX2 
and Osterix, attesting to osteogenic differentiation of 
MSC. It is known that RUNX2 is required for direct 
differentiation of MSC towards osteoblasts lineage 
cells and maintains cells in the immature stage (pre-
ostoblasts), while accumulation of Osterix promotes 
maturation of preosteoblasts and their differentiation 
into osteoblasts [5,7].
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Our aim was to study the expression of transcrip-
tion factors RUNX2 and Osterix upon addition of oste-
ogenic-conditioned medium concentrate to the culture 
medium to differentiate MSC towards the osteogenic 
direction.
MATERIALS AND METHODS
The experiments were carried out on culture of MSC 
obtained from Wistar rats (vivarium of Research In-
stitute of Pharmacology of Living Systems, Belgorod 
National Research University). All manipulations were 
carried out in accordance with GOST ISO 10993-
2:2006 and Directive 86/609/EEC On the Protection 
of Animals used for Scientific Purposes.
MSC were isolated from red bone marrow using 
commonly accepted method [2] and were seeded in 
25-cm2 flasks; the cells were expanded in complete 
culture medium (CCM) based on DMEM (Gibco, 
Thermo Fisher Scientific) supplemented with 10% 
fetal calf serum (HyClone) in a CO2 incubator MCO-
5AC (Panasonic) at 37°С, 100% humidity, and 5% 
СO2. After obtaining the required number of cells for 
in vitro experiments, the supernatant was removed 
from the flask, 5 ml 0.05% trypsin solution with EDTA 
(Capricorn Scientific) was added to remove and sub-
culture the cells. At this stage, rat MSC (2×106 cells 
per ml) were phenotyped (detection of positive expres-
sion of CD90 (MA1-81572, Thermo Fisher Scientific) 
and CD29 (17-0291-80e, BD Bioscience) and negative 
expression of CD45 (12-0461-80 Invitrogen), CD31 
(25-0310-80 BD Bioscience)) by flow cytometry us-
ing BD FACSCanto II and Software FACS Diva 8) [3] 
using facilities of industrial partner Innovation Center 
Biruch-NT.
The concentrate of osteogenic-conditioned me-
dium (cOCM) was obtained by culturing rat MSC in 
DMEM/F-12 growth medium (Gibco, Thermo Fisher 
Scientific) supplemented with 10% fetal calf serum (Hy-
Clone) at 5% СО2, 37°С, in a humid atmosphere. After 
obtaining sufficient number of cells, the nutrient medi-
um was removed, the cell monolayer was washed once 
with PBS. To stimulate osteogenic differentiation of 
MSC, CCM containing an osteoinductive supplement: 
dexamethasone (100 nM), ascorbic acid (50 μg/ml), 
and sodium β-glycerophosphate (10 mM) was used 
[12]. After a certain period of time, the osteoinduc-
tive medium was removed, the cell monolayer was 
washed with PBS, and the same amount of serum-free 
DMEM/F-12 growth medium without supplements 
was added. After culturing, a conditioned medium was 
collected and centrifuged at 3000 rpm for 10 min. The 
supernatant was passed through a 0.22-μ filter and 
concentrated by tangential flow ultrafiltration using 
a Vivaflow 200 system (Sartorius) that allows work-
ing with sample volumes from 0.1 liter to 1 liter in 
one step. For this, membrane modules with a cut-off 
threshold for molecules with a molecular weight of 
10 kDa were used, because the main pool of MSC 
secretome proteins lies above this value [10]. Diafiltra-
tion of cOCM was also carried out using this system 
according to manufacturer’s recommendations. Puri-
fied from salts cOCM was dried in a Rotavapor R-210 
vacuum rotary evaporator (Buchi). Dried cOCM was 
collected from a round bottom reaction flask using a 
spatula into a microcentrifuge tube with observance 
of aseptic principles and stored in a freezer at -20°C.
The supplement StemPro Osteogenesis Differen-
tiation kit (Life Technologies) to CCM was used as a 
positive control of osteoinductivity; CCM of standard 
composition without osteoinductive supplements was 
used as a negative control of osteoinductivity.
Prior to collection of osteogenic-conditioned 
medium, osteogenic differentiation of MSC was con-
firmed by alkaline phosphatase staining [1]. To this 
end, MSC were washed in PBS and fixed with 4% par-
aformaldehyde for 2 min. The fixed cells were washed 
with 1 ml wash PBS with 0.05% Tween-20 and incu-
bated with BCIP/NBT substrate (Sigma-Aldrich) at 
room temperature for 10 min. After washing, alkaline 
phosphatase staining in MSC was detected under an 
Eclipse Ti-U microscope (Nikon) and its intensity (in 
arb. units) in comparison with the negative control 
MSC was evaluated using specialized Nikon EZ-C1 
FreeViewer software (Nikon).
The obtained rat MSC culture was resuspended 
and seeded to 35-mm Petri dishes (SPL Lifesciences) 
in a volume of 200 μl (concentration 106 cells/ml). 
After 30-min incubation of MSC in a CO2 incubator at 
37°C, 100% humidity, and 5% CO2, 2 ml of CCM with 
osteogenic-conditioned medium at a ratio of 1:50 was 
added and the cells were cultured in a CO2 incubator 
at 37°C, 100% humidity, and 5% CO2.
On days 7 and 14, the expression of transcription 
factors RUNX2 and Osterix was studied in rat MSC 
culture [4] by the immunofluorescence method. The 
following reagents were used to identify transcription 
factors RUNX2 and Osterix in MSC: primary anti-
bodies to RUNX2 (ab76956; 1:50; Abcam) with Goat 
Anti-Mouse IgG H&L secondary antibodies (Alexa 
Fluor 488) (ab150113, 1:1000; Abcam) and primary 
antibodies to Osterix/Sp7 (ab22552, 1:500; Abcam) 
with Goat Anti-Rabbit IgG secondary antibodies H&L 
(Alexa Fluor 594) (ab150080, 1:1000; Abcam). All 
initial work with antibodies was carried out according 
to manufacturer’s instructions. Prior to addition of an-
tibodies, the culture medium was completely removed, 
2 ml PBS was added, and shaken for 1 min. Then, 
PBS was completely removed, the cells were fixed 
with 10% formalin for 30 min, washed with PBS, and 
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permeabilized in 0.1% Triton X-100 in PBS for 15 min 
at room temperature. After permeabilization, the cells 
were washed twice in PBS and incubated with 1% 
solution BSA in PBS was for 30 min. Then, the cells 
were again washed twice with PBS and primary anti-
RUNX2 or anti-Osterix antibodies in PBS (150 μl) 
were applied to the sample (directly to the bottom of 
a 35 mm Petri dish) and incubated for 1 h at room 
temperature. Then, the samples were washed twice 
with PBS and incubated with secondary antibodies in 
150 μl PBS for 1 h at room temperature in the dark. 
After double washing with PBS, cell fluorescence was 
recorded using a Digital Eclipse С1 Plus confocal laser 
scanning microscope (Nikon). The fluorescence inten-
sity of each cell and the number of cells in 10 fields of 
view were analysed. The proportion of RUNX2+ and 
Osterix+ cells was calculated by the formula: P (%)= 
B/A×100%, where P (%) is proportion of RUNX2+ and 
Osterix+ cells, А is the total number of cells per field 
of view, and B is the number of RUNX2+ or Osterix+ 
cells.
Statistical processing of the results was carried 
out using Statistica 6.0 software (StatSoft, Inc.) using 
Student’s t test and presented as M±SD. The differ-
ences were significant at p≤0.01.
RESULTS
Flow cytometry showed that the studied cells ex-
pressed CD29 (98.8%), CD90 (98.8%), CD45 (1.7%), 
and CD31 (0.3%), which allowed classifying them as 
MSC (Fig. 1). Analysis of the expression of alkaline 
phosphatase in MSC in CCM with osteoinductive sup-
plement (dexamethasone, ascorbic acid, and sodium 
β-glycerophosphate) confirmed osteogenic differentia-
tion of cells: 150.0±5.5 arb. units (vs 2.0±1.5 arb. units 
in negative control; p≤0.01).
Immunofluorescence analysis showed that the 
proportion of RUNX2+ MSC on day 7 of culturing 
both in the positive control and in the presence of 
cOCM was higher than in the negative control. On 
day 7, the proportion of RUNX2+ MSC was 57.54% 
(83.60±18.99 cells) in the negative control and 100% 
in the positive control (123.90±19.12 cells); in the 
presence of cOCM, the proportion of RUNX2+ MSC 
was also 100% (126.30±18.42 cells). The intensity of 
fluorescence of RUNX2+ MSC in the positive con-
trol was 929.67±171.65 arb. units; in the presence of 
cOCM, this parameter was 496.10±114.94 arb. units, 
which exceeded more than 11 times the fluorescence 
intensity in the negative control (36.56±21.65 arb. 
units; p≤0.01). These findings confirm osteoinductive 
properties of cOCM.
On 14 day of MSC culturing, a decrease in the 
proportion of RUNX2+ MSC to 51.69% (68.70±14.25 
cells) was observed in cultures with cOCM, while in 
positive and negative controls, these indicators did not 
change (Figs. 2, 3). The proportion of RUNX2+ MSC 
in the negative control was 54.70% (68.60±18.98 
cells) and in the positive control 100% (127.30±19.76 
cells). Interesting, that the intensity of RUNX2 fluo-
rescence in all MSC decreased by day 14 of culturing 
to 696.33±170.33 arb. units in the positive control, 
to 302.77±122.92 arb. units in MSC cultured with 
cOCM, and to 33.90±17.21 arb. units in the negative 
control (p≤0.01).
Analysis of the expression of Osterix in MSC re-
vealed no Osterix fluorescence in the negative control 
on days 7 and 14. Osterix fluorescence was also absent 
on day 7 in MSC cultured in the presence of cOCM. 
On day 7 the fluorescence of Osterix+ MSC were de-
tected in the positive control: 51.68% (64.70±17.06 
Fig. 1. Expression of CD90, CD31, CD45, and CD29 on the surface of MSC isolated from rat red bone marrow.
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cells); fluorescence intensity 139.33±67.28 arb. units. 
On day 14, Osterix+ MSC were detected both in the 
positive control and in cultures incubated with cOCM. 
In the positive control, the proportion of fluorescent 
cells was 100% (124.80±19.35 cells), while in the 
presence of cOCM, the proportion of fluorescent cells 
was 43.91% (62.60±15.09 cells). The Osterix fluores-
cence intensity in MSC was maximum in the positive 
control (456.10±162.98 arb. units) and lower in MSC 
cultured with cOCM (319.67±166.33 arb. units).
The expression of RUNX2 transcription factor at 
the level of background values in the negative con-
trol MSC (without osteoinductive factors) could be 
explained by the fact that MSC were passaged only 
several times and retained their multipotency. In the 
course of MSC differentiation towards osteogenic 
lineage cells, the expression of transcription factor 
RUNX2 decreased and expression of transcription 
factor Osterix increased. The highest expression of 
Osterix transcription factor was observed on day 14 of 
culturing both in the positive control with osteogenic 
StemPro supplement and in the presence of cultured 
the studied cOCM.
Thus, the concentrate of osteogenic-conditioned 
medium containing a complex of bioactive substances 
with a molecular weight >10 kDa stimulates differen-
tiation of MSC into osteoblasts, which is confirmed 
by high expression of transcription factors RUNX2 
and Osterix in comparison with the negative control. 
These findings indicate the possibility of obtaining of 
cOCM with a complex of paracrine factors of directed 
activity.
Fig. 2. Immunofluorescence of rat MSC: expression of RUNX2 
on day 14 without osteoinductive supplement (a) and in the 
presence of cOCM (b) or StemPro Osteogenesis Differentiation 
kit supplement (c), ×100.
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Fig. 2. Immunofluorescence of rat MSC: expression of Osterix on day 14 in the presence of cOCM (b) and StemPro Osteogenesis 
Differentiation kit supplement (c), ×100.
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